About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Brown Seaweed as a Breast Cancer Preventive | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1/2NCT01204957

Brown Seaweed as a Breast Cancer Preventive

Japanese postmenopausal women in Japan have about one ninth the rate of American postmenopausal women. Rates of breast cancer double even after just ten years among Japanese women who migrate to the U...

Lead sponsor: University of South Carolina•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University of South Carolina

Collaborators

Susan G. Komen Breast Cancer Foundation

33 healthy postmenopausal women were randomized to 6 wk seaweed then 1 wk seaweed plus soy or 6 wk placebo then 1 wk placebo plus soy. Blood and urine samples were collected at the end of each treatment period and analyzed for estrogen, homocysteine, antioxidants, insulin-like growth factors and thyroid hormones. Urine was analyzed for phytoestrogens and iodine.

Age

18 - 80 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Postmenopausal (self-reported cessation of menstruation 1 y prior to enrollment)
•If breast cancer survivor, all therapy completed at least 6 months prior to enrollment
•Agreed to eat their normal diet, avoiding seaweeds and phytoestrogen-rich foods,
•Restricting alcoholic intake to #2 drinks (24 g alcohol)/wk -Continuing habitual intake of vitamins, supplements, and medications during the study. -

Exclusion Criteria

•No allergies to seaweed, soy, shellfish, or iodine
•No current use of tobacco;
•No thyroid dysfunction or treatment within the previous 5 y;
•Negative thyroid peroxidase antibodies as determined by screening;
•No hormone replacement therapy or for breast cancer survivors, no chemotherapy or radiation treatments within the preceding 6 mo
•No history of cancer (other than breast cancer)
•No current gastrointestinal disorders or diabetes; omnivorous eating habits, including meat and dairy products at least twice/wk
•No oral antibiotics, iodine containing medications, or corticosteroids treatment within the previous 3 mo.

Related studies

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Advanced Breast Cancer

RECRUITINGPhase 2

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998 · Breast Cancer

RECRUITINGPhase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

RECRUITINGPhase 4

A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients

NCT07578064 · Breast Cancer, Bone Marrow Suppression

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 6, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment33

Start dateOct 1998

Last updatedApr 6, 2015

Condition

Locations shown

University of Massachusetts

Worcester, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 6, 2015Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions